Chemical Biology and Drug Design

NOVEMBER 13, 2023

SARS-CoV-2 is responsible for the coronavirus disease of 2019 (COVID-19) which is one of the most widespread and powerful infections affecting human lungs. WHO proclaimed the outbreak of the Ebola virus disease (EVD), in 2014 that killed hundreds of people in West Africa.

Vaccine 100

Vaccine Laboratories RNA Clinical Development 100

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52

PLOS: DNA Science

JULY 27, 2023

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus.

Disease 98

Disease DNA Virus RNA 98

Codon

MARCH 20, 2023

Basic Science A trailing ribosome speeds up RNA polymerase at the expense of transcript fidelity via force and allostery. Ribozyme-mediated RNA synthesis and replication in a model Hadean microenvironment. Assembly of metabolons in yeast using Cas6-mediated RNA scaffolding. elegans neurons for single-cell RNA sequencing.

Virus 52

Virus Engineering RNA Small Molecule 52

Chemical Biology and Drug Design

JULY 27, 2023

cells induced by poly (I:C) were treated with or without PA, and then RNA-sequencing, GO and KEGG analysis were carried out to obtain the five differentially expressed genes (IL-1β, HMOX1, PTGS2, Abca1, and P65), which were verified by QRT-PCR and western blot. RNA-sequencing was applied to analyze the differentially expressed genes (DEGs).

RNA 100

RNA Virus Disease Drugs 100

PLOS: DNA Science

JUNE 13, 2024

The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. Her points: 1. Coincidence? I’ve never thought so.

Virus 52

Virus RNA DNA Science 52

Drug Target Review

JULY 11, 2023

In the quest to combat and eradicate diseases, scientists and researchers are increasingly turning to the immense potential of artificial intelligence (AI) as a tool. It was here that the Impact Medicine Fund was raised as a concept around wellness for those with disease, with the ambition of unlocking some of this vast potential.

Disease 75

Disease RNA Small Molecule Clinical Development 75

Drug Target Review

JUNE 28, 2023

Using a synthetic guide RNA (gRNA), scientists can target a specific DNA sequence and employ Cas9 to cut it. Using this mechanism, scientists can now silence genes to elucidate their roles in disease phenotype, which can benefit target discovery. It was also discovered that the Cas enzyme was responsible for DNA cleavage.

Engineering 98

Engineering DNA Immune Response RNA 98

Broad Institute

MAY 16, 2024

By Allessandra DiCorato May 16, 2024 Credit: Deverman lab Brain vasculature (in blue) surrounded by RNA (in orange) transcribed from the gene delivered to the brain in humanized mice using an engineered AAV targeting the human transferrin receptor.

Therapies 137

Therapies FDA Approval Engineering Disease 137

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. If this genetic material is further replicated, defective RNA copies are produced and the pathogen can no longer spread. ” Mutations in the genome stop the virus. Molnupiravir has a lot of potential.”

RNA 52

RNA Virus Clinical Trials Drugs 52

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Licensing 52

Licensing Licensing Therapies Disease 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. “We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. Breathe in, exhale. But now, we’re one step closer.

Vaccine 52

Vaccine Disease Immune Response Virus 52

Broad Institute

MARCH 22, 2024

Messenger RNAs with multiple “tails” could lead to more effective therapeutics By Corie Lok March 22, 2024 Breadcrumb Home Messenger RNAs with multiple “tails” could lead to more effective therapeutics Scientists have engineered long lasting mRNAs that increased therapeutic protein production in cells and animals.

Engineering 140

Engineering Protein Production RNA Vaccine 140

Broad Institute

AUGUST 31, 2023

Related News Next generation prime editing systems move closer to possible therapeutic applications New CRISPR genome editing system offers a wide range of versatility in human cells Prime editing technologies allow scientists to precisely edit the genome in a variety of ways and could one day be used to treat genetic diseases.

DNA 145

DNA Engineering RNA Laboratories 145

Drug Target Review

SEPTEMBER 4, 2023

There have been several studies that have reported the ability of infectious disease agents to be drug resistant. Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. 7,13 The use of Plants extract is important in drug discovery.

Drugs 111

Drugs RNA DNA Disease 111

Drug Target Review

OCTOBER 2, 2024

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. This approach can be highly targeted, with the potential to correct mutations that lead to specific diseases or deliver therapeutic genes to improve heart function.

Therapies 98

Therapies Disease Engineering RNA 98

Drug Target Review

FEBRUARY 7, 2024

For example, innate immune peptides being imitated by SARS-CoV-2 fragments have a special ability to organise double stranded RNA into structures that strongly amplify activation of the human innate immune system in autoimmune diseases. Maybe the next pandemic respiratory virus will be an influenza virus rather than a coronavirus.

RNA 69

RNA Virus Immune Response Engineering 69

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 81

DNA Laboratories Hospitals Virus 81

KIF1A

FEBRUARY 4, 2024

Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. But similar looking diseases won’t necessarily respond to the same treatments, which is why it’s so important to find accurate diagnoses. What is an allele specific ASO?

RNA 52

RNA DNA Disease Trials 52

New Drug Approvals

SEPTEMBER 6, 2024

US10071079, Example 15 Ref WO2018005586 [link] The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to TLR modulation, such as inflammatory and autoimmune diseases, and methods of inhibiting the activity of TLRs in a mammal.

RNA 62

RNA Clinical Trials DNA Disease 62

The Pharma Data

DECEMBER 5, 2020

5, 2020 — A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Bluebird’s method “uses a virus to drop an entire gene encoding a new hemoglobin. SATURDAY, Dec.

Therapies 52

Therapies Disease Medical Schools Virus 52

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context.

Therapies 59

Therapies RNA Protein Expression DNA 59

Broad Institute

DECEMBER 13, 2023

Related news Researchers map brain cell changes in Alzheimer’s disease Courtesy of the Chen and Macosko labs. The researchers also discovered clues about cellular function and the potential roles of brain structures in disease. Courtesy of the Chen and Macosko labs. Courtesy of the Chen and Macosko labs.

DNA 140

DNA Virus Research Engineering 140

New Drug Approvals

AUGUST 22, 2023

1951476-79-1 Hepatitis B virus (HBV) is an infectious disease that targets the liver resulting in either an acute infection, with symptoms arising in 45 to 160 days, or a chronic infection, which 350 million people worldwide are affected by. EIDD-2173; also known as ATI-2173 Fosclevudine alafenamide Phase 2 Molecular Weight 529.45

RNA 52

RNA DNA Virus Treatment 52

Drug Target Review

MARCH 21, 2024

Dystrophin is mutated in Duchenne muscular dystrophy (DMD), a rare disease that causes progressive muscle weakness and atrophy. Because mRNA is not a virus, it doesn’t have to meet biosafety requirements for manufacturing and administration that an AAV approach would need. Of note, mRNA is redosable as opposed to AAV.

Therapies 64

Therapies RNA Immune Response Treatment 64

The Pharma Data

JANUARY 21, 2021

President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. People also haven’t been provided clear messaging on the messenger RNA vaccines, Osterholm added.

Vaccine 52

Vaccine Virus RNA Research 52

Broad Institute

NOVEMBER 6, 2024

They also saw an increase in abundance of several immune cell subsets, as well as an increase in abundances of certain cellular groupings composed of specific cytotoxic T cells, conventional dendritic cells (cDCs), and inflammatory fibroblasts that were found together in the hearts of patients with active disease. Online November 6, 2024.

Immune Response 118

Immune Response Medical Schools Clinical Trials Treatment 118

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., “Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. Chief Executive Officer and Founder of Atea Pharmaceuticals.

RNA 52

RNA Pharmaceuticals Virus Small Molecule 52

The Pharma Data

MARCH 8, 2022

Also, the incidence of severe disease progression was observed to be significantly reduced. The virus carries the information to produce a series of proteins, capable of inhibiting antiviral recognition systems of the infected cell. Camouflage protects virus from immune system. Researchers led by Prof.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

DECEMBER 3, 2020

Additionally, “There is not any available single test for the entire stage of the disease,” Gunduz said in a statement. Consequently, performing an immunoassay in the early stages of an infection will be negative because the antibodies cannot be produced yet, even though the disease is present.

RNA 52

RNA Virus DNA Disease 52

Broad Institute

JANUARY 30, 2024

Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections.

Hospitals 137

Hospitals Medical Schools Virus Science 137

PerkinElmer

JUNE 14, 2021

Meanwhile, researchers are continuing to investigate possible treatments for patients suffering with the disease. In October last year, remdesivir was the first drug approved by the FDA for treating the SARS-CoV-2 virus. After three days, viral replication supernatants were collected, and viral RNA was extracted.

Virus 52

Virus RNA Vaccine Treatment 52

The Pharma Data

JANUARY 31, 2021

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. . CHENGDU, China , Feb.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. 18, 2020 ).

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

The Pharma Data

DECEMBER 3, 2020

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Codon

SEPTEMBER 29, 2024

The earliest ones relied on simple linear regression and attempted to correlate genetic variations with observable traits or disease risks — such as drug metabolization rates or cancer susceptibility. Over the decade, entire categories of diseases disappeared. 2024 Statistical models of organisms have existed for decades.

Engineering 130

Engineering Virus DNA Therapies 130